Canine Osteosarcoma Clinical Trial | ELIAS Animal Health
ELIAS Animal Health recently conducted a clinical trial to evaluate its ELIAS cancer immunotherapy (ECI®) – a vaccine-enhanced adoptive cell therapy – combined with surgery as a treatment for canine osteosarcoma.
This study evaluated a novel immunotherapy approach in dogs with osteosarcoma and combined it with surgical intervention to assess potential clinical benefits and safety profile.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC